future of glp 1 drugs Didn't take much for the time magazine to do a flip! From “The big promise” to “A metabolic whiplash” A new study came out yesterday that showed that stopping GLP-1 for GLP-1 2.0: Where the Next

Hypertension 58 , 784790 (2011)

Potential Cardiovascular Benefits: Ongoing REDEFINE 3 trials are assessing whether CagriSema can reduce cardiovascular risks, a major concern for people with obesity or type 2 diabetes

In the Phase 2 ACCESS II study, aleniglipron achieved clinically meaningful and statistically significant placebo-adjusted mean weight loss of 16.3% (39 lbs

Some animal studies have indicated potential benefits in wound healing and tissue repair, though these findings have not been replicated in rigorous human clinical trials

Accessed September 1, 2023

Presented for research literature review only Mayer D et al